Nuwellis, Inc. · NASDAQ:NUWE
Nuwellis — IPO Roadshow (June 2026)
24 slides from Nuwellis's IPO roadshow presentation, Jun 2, 2026
Slide 1: Accelerating Growth in Cardiorenal Care
Investor Presentation June 2026 Accelerating Growth in Cardiorenal Care Nuwellis, Inc. | Nasdaq NUWE | For Investor Purposes Only: Not for Product Promotion | 2026 Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Relating to Form S-1, as amended Registration Statement No. 333-296198 June 1,
Slide 2: Safe Harbor Statement
Aquadex SmartFlow® is a registered trademark of Nuwellis, Inc. Aquadex ® is a trademark of Nuwellis, Inc. Safe Harbor Statement Financial and Statistical DataThis presentation also contains estimates and other statistical data made by independent parties and by us relating to market shares and other
Slide 3: Free Writing Prospectus
Free Writing Prospectus The Company has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. The registration statement can be accessed here https://www.sec.gov/Archives/edgar/data/1506492/000114036126022629/ny20073226x1_s1.htm. B
Slide 4: Risk Statement
Risk Statement Investing in our securities includes a high degree risk. You should consider carefully the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, including specific risk
Slide 5: Strong Q4 2025 and Q1 2026 commercial momentum
Strong Q4 2025 and Q1 2026 commercial momentum Operational Discipline Executing initiatives to reduce monthly cash burn in Q4 to $500K per month, a reduction of ~60% from Q1 levels. Spend reductions driven mainly by project and hiring delays, plus lower consulting costs Exited unprofitable OUS opera
Slide 6: Nuwellis Is Transitioning Toward Scaled Commercial Growth
Nuwellis Is Transitioning Toward Scaled Commercial Growth Pediatrics, now ~50% of revenue, continues to accelerate across leading children’s hospitals Critical care adoption expanding across ICU and cardiac surgery programs Commercial Momentum Driven by High-Growth Clinical Categories:
Slide 7: Our Solution: Aquadex
Our Solution Aquadex®A clinically proven therapy for precise, predictable fluid removal1 Low-volume ultrafiltration designed for critically ill patients Allows controlled fluid removal when diuretics fail Adopted in ICU, cardiac surgery, and pediatric critical care programs 1: Pinney, S et. al., J A
Slide 8: Expanding Beyond Fluid Removal Into Critical Care Monitoring
Expanding Beyond Fluid Removal Into Critical Care Monitoring Leveraging our ICU and pediatric commercial infrastructure to expand into adjacent monitoring and therapy markets CURRENT COMMERCIAL ENGINE Precision fluid removal platform deployed across ICU and pediatric centers Expands revenue opportun
Slide 9: Fluid Overload Drives Mortality, Readmissions and ICU Costs
Fluid Overload Drives Mortality, Readmissions and ICU Costs Fluid Overload is a leading cause of costly hospital readmission post 30 days following cardiac surgery2 2. Iribarne A, et al. Ann Thorac Surg. 2014; 98(4): 1274-80. 3. Vaara ST et al. Crit Care.2012; 16: 1-11. 4: Sutherland SM, et al. Am J
Slide 10: Why Hospitals Are Adopting Precision Fluid Management
Why Hospitals Are Adopting Precision Fluid Management 7. Messmer AS, Zingg C, Müller M, Gerber JL, Schefold JC, Pfortmueller CA. Fluid overload and mortality in adult critical care patients: A systematic review and meta-analysis of observational studies. Crit Care Med. 2020;48(12):1862–1870 8. McIlr
Slide 11: Nuwellis' Total U.S. Platform Potential Opportunity Exceeds $4.2B Today
Nuwellis’ Total U.S. Platform Potential Opportunity Exceeds $4.2B Today 11: See Appendix Inpatient HF $1B Market11 Critical Care $900M Market11 Pediatrics $160M Market11 $4.2B Clinical Addressable U.S. Market Outpatient HF $770M Market11 Aquadex, Vivian, and Clarity collectively address an enormous
Slide 12: Pediatric Adoption of Aquadex Validates Market Need
Providers are increasingly seeking out Aquadex for use with children, validating both the clinical demand and the growing commercial footprint in pediatric centers. Pediatric Adoption of Aquadex Validates Both the Market Need and the Pathway for a Dedicated Pediatric Solution Adopted in 47 of the to
Slide 13: Aquadex Demonstrated Improved Survival in Pediatric Setting
Aquadex Demonstrated Improved Survival in Pediatric Setting “For our babies born with diseased or absent kidneys, Aquadex has given them a chance at life because in the past, there were no options to treat these patients.” Kara Short, MSN, CRNP, NICU nurse practitioner at Alabama Children’s Hospital
Slide 14: FDA Regulatory Milestone Supports Pediatric Growth Expansion
FDA Regulatory Milestone Supports Pediatric Growth Expansion Successfully completed FDA pre-submission meeting for proposed Aquadex label expansion to pediatric patients ≥5 kg Proposed expansion supported by: 10+ years of published pediatric clinical experience Real-world utilization at leading pedi
Slide 15: Vivian: Developing our dedicated pediatric solution
Vivian™Developing our dedicated pediatric solution Currently in development and supported by a $3M NIH grant. Ultra-low ECV (29–67 mL) for neonatal + small-child CRRT Engineered for patients as small as 2.5kg with unique Hematocrit and SVO2 sensor safety features Integrated UF, CVVH, and CVVHD thera
Slide 16: ClarityPRIME Systems Expands Nuwellis Into Smart Fluid Monitoring
ClarityPRIME* Systems Expands Nuwellis Into Smart Fluid Monitoring 1. Addresses a Critical Need in Cardiac Surgery & Critical Care Real-time urine output and electrolyte data are essential for early detection of AKI. 2. Enters a High-Growth, Underpenetrated Market Targets the emerging automated urin
Slide 17: Turning Higher Outpatient Reimbursement into Better Outcomes
With the reassignment of CPT 0692T in early 2025 – from $413 to $1,591 per day – hospital-based outpatient programs are growth opportunity for Nuwellis. Cost Avoidance Recurring Revenue Higher reimbursement creates a predictable, continuous revenue stream Proactive hospital-based outpatient care hel
Slide 18: High-Margin Recurring Revenue Model
High-Margin Recurring Revenue Model Aquadex Console Capital Equipment Flexible acquisition models: purchase, lease or rental Disposables Recurring Revenue Increasing utilization as adoption spreads One-time CapEx purchase Price point: high-value Single-use for every treatment High-margin
Slide 19: Nuwellis Leadership Team
Nuwellis Leadership Team Over 200 years of combined experience in clinical practice and the medical device industry, including major tenures at J&J, Boston Scientific, Medtronic, and Abbott/St. Jude Medical. John Erb Chief Executive Officer Ryan Marthaler Vice President of Product Marketing and Busi
Slide 20: Capitalization Overview
Capitalization Overview As of May 27, 2026 Common Equivalents Common Stock 2,942,048 Preferred Stock* 80,276 Warrants (weighted avg. exercise price: $4.57) 3,996,000 Pre-funded Warrants 558,000 Options (weighted avg. exercise price: $4.59) 61,422 Fully Diluted, including Pre-funded Warrants 7,637,74
Slide 21: Driving Revenue Growth with Improved Operating Discipline
Driving Revenue Growth with Improved Operating Discipline Commercial Focus Prioritizing investment in pediatrics, critical care application expansion, and outpatient growth Supporting continued commercial momentum in core markets Pursuing select distribution partnerships and strategic growth opportu
Slide 22: Target Key 2026-2027 Milestones
Target Key 2026-2027 Milestones Target Date Milestone Q2 2026 Pediatric 5kg label expansion FDA pre-sub meeting completed Q3 2026 Publish ULTRA-Peds data Q3 2026 FDA 510k submission for Pediatric indication expansion to 5kg (from 20kg) Q4 2026 Announce strategic partnership/distribution agreement Q4
Slide 23: Thank You
Thank You
Slide 24: Market Size Sources
Market Size Sources Heart Failure – Inpatient Incidence of HF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494150/ Annual HF Hospitalizations: Costanzo MR, et al. J Am Coll Cardiol. 2017 May 16;69(19):2428-2445 Insufficient diuretic response: https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILUR